Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Outlook Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Outlook Therapeutics, Inc.

OTLK

Outlook Therapeutics, Inc.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company developing ophthalmic formulations of bevacizumab for retinal diseases like wet AMD, DME, and BRVO. Its flagship product, ONS-5010/LYTENAVA, is approved in the EU and UK and aims to provide a safe, effective, and affordable on-label alternative to off-label repackaged bevacizumab. The company focuses on regulatory approval, strategic collaborations, and targeted commercialization in global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Outlook Therapeutics, Inc.

1
1
Outlook Therapeutics, Inc. Outlook Therapeutics Reports Q2 Fiscal 2026 Revenue Growth to $127,439 Amid Ongoing Losses

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Outlook Therapeutics, Inc. Outlook Therapeutics Reports $23.1 Million Net Loss and Negative Revenue for December 2025 Quarter

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Outlook Therapeutics, Inc. Outlook Therapeutics Reports Fiscal Year 2025 Results and Focus on U.S. Approval

Via official filing (AI summary) | 6 months ago | 0 comments

4
1
Outlook Therapeutics, Inc. Outlook Therapeutics Reports $1.5 Million Revenue in Q3 2025, Faces $20.2 Million Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Outlook Therapeutics, Inc. Outlook Therapeutics Reports $46.4M Net Loss, Prepares for ONS-5010/LYTENAVA Launch

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Outlook Therapeutics, Inc. Outlook Therapeutics Reports $17.4M Net Income Turnaround, Prepares for EU and UK Launch of ONS-5010/LYTENAVA

Via official filing (AI summary) | over 1 year ago | 0 comments